- Home
- FBRX vs CRBU Comparison
FBRX vs CRBU Comparison
Compare FBRX & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBRX
- CRBU
- Stock Information
- Founded
- FBRX N/A
- CRBU 2011
- Country
- FBRX United States
- CRBU United States
- Employees
- FBRX N/A
- CRBU N/A
- Industry
- FBRX Biotechnology: Pharmaceutical Preparations
- CRBU Medicinal Chemicals and Botanical Products
- Sector
- FBRX Health Care
- CRBU Health Care
- Exchange
- FBRX Nasdaq
- CRBU Nasdaq
- Market Cap
- FBRX 84.0M
- CRBU 93.0M
- IPO Year
- FBRX N/A
- CRBU 2021
- Fundamental
- Price
- FBRX $12.39
- CRBU $1.25
- Analyst Decision
- FBRX Strong Buy
- CRBU Strong Buy
- Analyst Count
- FBRX 2
- CRBU 4
- Target Price
- FBRX $61.00
- CRBU $8.50
- AVG Volume (30 Days)
- FBRX 167.7K
- CRBU 1.8M
- Earning Date
- FBRX 08-13-2025
- CRBU 08-05-2025
- Dividend Yield
- FBRX N/A
- CRBU N/A
- EPS Growth
- FBRX N/A
- CRBU N/A
- EPS
- FBRX N/A
- CRBU N/A
- Revenue
- FBRX N/A
- CRBU $9,918,000.00
- Revenue This Year
- FBRX N/A
- CRBU $12.83
- Revenue Next Year
- FBRX N/A
- CRBU N/A
- P/E Ratio
- FBRX N/A
- CRBU N/A
- Revenue Growth
- FBRX N/A
- CRBU N/A
- 52 Week Low
- FBRX $4.11
- CRBU $0.66
- 52 Week High
- FBRX $28.68
- CRBU $3.00
- Technical
- Relative Strength Index (RSI)
- FBRX 56.82
- CRBU 54.53
- Support Level
- FBRX $10.15
- CRBU $1.20
- Resistance Level
- FBRX $13.28
- CRBU $1.44
- Average True Range (ATR)
- FBRX 1.85
- CRBU 0.11
- MACD
- FBRX -0.16
- CRBU -0.01
- Stochastic Oscillator
- FBRX 30.06
- CRBU 52.50
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.